LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A.

    Abache, Toufik / Fontayne, Alexandre / Grenier, Dominique / Jacque, Emilie / Longue, Alain / Dezetter, Anne-Sophie / Souilliart, Béatrice / Chevreux, Guillaume / Bataille, Damien / Chtourou, Sami / Plantier, Jean-Luc

    Haematologica

    2020  Volume 105, Issue 9, Page(s) 2335–2340

    Abstract: Rendering coagulation factor X sensitive to thrombin was proposed as a strategy that can bypass the need for factor VIII. In this paper, this non-replacement strategy was evaluated in vitro and in vivo in its ability to correct factor VIII but also ... ...

    Abstract Rendering coagulation factor X sensitive to thrombin was proposed as a strategy that can bypass the need for factor VIII. In this paper, this non-replacement strategy was evaluated in vitro and in vivo in its ability to correct factor VIII but also factor IX, X and XI deficiencies. A novel modified factor X, named Actiten, was generated and produced in the HEK293F cell line. The molecule possesses the required post-translational modifications, partially keeps its ability to be activated by RVV-X, factor VIIa/tissue factor, factor VIIIa/factor IXa and acquires the ability to be activated by thrombin. The potency of the molecule was evaluated in respective deficient plasmas or hemophilia A plasmas, for some with inhibitors. Actiten corrects dose dependently all the assayed deficient plasmas. It is able to normalize the thrombin generation at 20 μg/mL showing however an increased lagtime. It was then assayed in a rabbit antibody-induced model of hemophilia A where, in contrast to recombinant factor X wild-type, it normalized the bleeding time and the loss of hemoglobin. No sign of thrombogenicity was observed and the generation of activated factor X was controlled by the anticoagulation pathway in all performed coagulation assays. This data indicates that Actiten may be considered as a possible non replacement factor to treat hemophilia's with the advantage of being a zymogen correcting bleedings only when needed.
    MeSH term(s) Animals ; Factor IX ; Factor VIII/genetics ; Factor VIIa ; Factor X/genetics ; Hemophilia A/drug therapy ; Hemophilia A/genetics ; Rabbits ; Thrombin
    Chemical Substances Factor VIII (9001-27-8) ; Factor IX (9001-28-9) ; Factor X (9001-29-0) ; Factor VIIa (EC 3.4.21.21) ; Thrombin (EC 3.4.21.5)
    Language English
    Publishing date 2020-09-01
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2019.219865
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies.

    Bas, Mathilde / Terrier, Aurélie / Jacque, Emilie / Dehenne, Aurélie / Pochet-Béghin, Virginie / Beghin, Cécile / Dezetter, Anne-Sophie / Dupont, Gilles / Engrand, Anaïs / Beaufils, Benjamin / Mondon, Philippe / Fournier, Nathalie / de Romeuf, Christophe / Jorieux, Sylvie / Fontayne, Alexandre / Mars, Lennart T / Monnet, Céline

    Journal of immunology (Baltimore, Md. : 1950)

    2019  Volume 202, Issue 5, Page(s) 1582–1594

    Abstract: ... The long ... ...

    Abstract The long serum
    MeSH term(s) Animals ; Antibodies/blood ; Antibodies/chemistry ; Antibodies/therapeutic use ; HEK293 Cells ; Half-Life ; Humans ; Immunoglobulin Fc Fragments/blood ; Immunoglobulin Fc Fragments/chemistry ; Immunoglobulin G/blood ; Immunoglobulin G/chemistry ; Immunoglobulin G/therapeutic use ; Mice ; Mice, Knockout
    Chemical Substances Antibodies ; Immunoglobulin Fc Fragments ; Immunoglobulin G
    Language English
    Publishing date 2019-01-25
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 3056-9
    ISSN 1550-6606 ; 0022-1767 ; 1048-3233 ; 1047-7381
    ISSN (online) 1550-6606
    ISSN 0022-1767 ; 1048-3233 ; 1047-7381
    DOI 10.4049/jimmunol.1800896
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern.

    Fournier, Nathalie / Jacque, Emilie / Fontayne, Alexandre / Derache, Delphine / Dupont, Gilles / Verhaeghe, Lucie / Baptista, Linda / Dehenne, Aurélie / Dezetter, Anne-Sophie / Terrier, Aurélie / Longue, Alain / Pochet-Beghin, Virginie / Beghin, Cecile / Chtourou, Sami / de Romeuf, Christophe

    mAbs

    2018  Volume 10, Issue 4, Page(s) 651–663

    Abstract: Plasmacytoid dendritic cells (pDCs) play a central role for both innate and adaptive antiviral responses, as they direct immune responses through their unique ability to produce substantial concentrations of type I interferon (IFNs) upon viral encounter ... ...

    Abstract Plasmacytoid dendritic cells (pDCs) play a central role for both innate and adaptive antiviral responses, as they direct immune responses through their unique ability to produce substantial concentrations of type I interferon (IFNs) upon viral encounter while also activating multiple immune cells, including macrophages, DCs, B, natural killer and T cells. Recent evidence clearly indicates that pDCs also play a crucial role in some cancers and several auto-immune diseases. Although treatments are currently available to patients with such pathologies, many are not fully efficient. We are proposing here, as a new targeted-based therapy, a novel chimeric monoclonal antibody (mAb) that mediates a strong cellular cytotoxicity directed against a specific human pDC marker, CD303. This antibody, ch122A2 mAb, is characterized by low fucose content in its human IgG1 constant (Fc) region, which induces strong in vitro and in vivo activity against human pDCs. We demonstrated that this effect relates in part to its specific Fc region glycosylation pattern, which increased affinity for CD16/FcγRIIIa. Importantly, ch122A2 mAb induces the down-modulation of CpG-induced IFN-α secretion by pDCs. Additionally, ch122A2 mAb shows in vitro high pDC depletion mediated by antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis. Remarkably, in vivo ch122A2 mAb efficacy is also demonstrated in humanized mice, resulting in significant pDC depletion in bloodstream and secondary lymphoid organs such as spleen. Together, our data indicates that ch122A2 mAb could represent a promising cytotoxic mAb candidate for pathologies in which decreasing type I IFNs or pDCs depleting may improve patient prognosis.
    MeSH term(s) Animals ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/pharmacology ; Dendritic Cells/drug effects ; Dendritic Cells/immunology ; Humans ; Lectins, C-Type/antagonists & inhibitors ; Membrane Glycoproteins/antagonists & inhibitors ; Mice ; Receptors, Immunologic/antagonists & inhibitors ; Recombinant Proteins/immunology ; Recombinant Proteins/pharmacology
    Chemical Substances Antibodies, Monoclonal ; CLEC4C protein, human ; Lectins, C-Type ; Membrane Glycoproteins ; Receptors, Immunologic ; Recombinant Proteins
    Language English
    Publishing date 2018-04-10
    Publishing country United States
    Document type Journal Article
    ISSN 1942-0870
    ISSN (online) 1942-0870
    DOI 10.1080/19420862.2018.1451283
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top